Nitroglycerin as an indicator for the presence of coronary heart disease

Canadian Pharmaceutical Journal

Volumn 132, Issue 8, 1999, Pages 32-36

  Tsuyuki, Ross T ^a   Olson, Kari L ^a   Teo, Koon K ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCERYL TRINITRATE;

ARTICLE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PATIENT EDUCATION; PHARMACEUTICAL CARE; PHARMACIST; PREVENTIVE MEDICINE; SUBLINGUAL DRUG ADMINISTRATION;

EID: 0032786109     PISSN: 08286914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.
2. Anon. A report from the trenches. Pharm Pract 1996;12(12):25-41.
3. Raisch DW. Barriers to providing cognitive services. Am Pharm 1993;NS33:54-58.
4. Miller MJ, Ortmeier BG. Factors influencing the delivery of pharmacy services. Am Pharm 1995;NS35:39-45.
5. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology. A basic science for clinical medicine. 2nd ed. Toronto: Little, Brown and Co., 1991:85.
6. Teo KK. Coronary artery disease prevention: Better management of dyslipidemias required. Can J Cardiol 1997;13:127-8.
7. Pearson TA, Brown WV, et al. Lipids. Workshop IV. AHA Prevention Conference III. Behavior Change and Compliance. Keys to improving cardiovascular health. Circulation 1993;88:1397-1401.
8. Clinical Quality Improvement Network (CQIN) Investigators. Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol 1995;76:570-73.
9. Tsuyuki RT, Johnson JA, Teo KK, Ackman ML, Biggs R, Cave A, et al., for the SCRIP Investigators. Study of Cardiiovascular Risk Intervention by Pharmacists (SCRIP): A randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. Ann Pharmacother 1999; 33, 910-9.
10. The Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4,606 acute care patients With congestive heart failure. The relative importance of age, sex, and medical therapy. Arch Int Med, 1996;156:1669-73.
11. Tsuyuki RT, Teo KK, et al. Mortality risk and patterns of practice in 2070 patients with acute myocardial infarction 1987-92. The relative importance of age, sex, and medical therapy Chest 1994,105:1687-92.
12. The Clinical Quality Improvement Network (CQIN) Investigators. Influence of a critical path management tool in the treatment of acute myocardial infarction. Am J Managed Care 1998,4:1243-51.
13. The Clinical Quality Improvement Network Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998;14:695-702.
14. Soumerai SB, McLaughlin TJ, et al. Adverse outcomes of under use of (-blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-21.
15. McLaughlin TJ, Soumerai SB, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction. Arch Intern Med 1996;156:799-805.
16. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994,308:81-106.